A two-year clinical trial that compared three drugs for diabetic macular edema (DME) found that gains in vision were greater for participants receiving the drug Eylea than for those receiving Avastin, but only among participants starting treatment with 20/50 or worse vision. Gains after two years were about the same for Eylea and Lucentis. The three drugs yielded similar gains in vision for patients with 20/32 or 20/40 vision at the start of treatment.